Pharma

Your Article Summary

See Latest Articles

Novogen Cash Reserves $25.4M, Phenoxodiol Receives US FDA Clearance for Phase III Human Trial
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/28/06

Pharmaceutical company Novogen Limited, has ended the 2005/06 financial year with solid cash reserves and US Food and Drug Administration (FDA) clearance for the final phase of human clinical testing of its lead anti-cancer drug, phenoxodiol. Revenue for the year ended 30 June, 2006, was $13.9 million, a 3.2 percent improvement over the previous corresponding period of $13.4 million

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09

A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09

Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09

See All of Drug Trials